Digital pathology provider Proscia has been chosen by the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centres in Europe, to deploy its Concentriq Dx platform. NKI is transitioning to Concentriq Dx to expand its digital pathology practice, laying the foundation for its pathologists to deliver personalised diagnoses that better inform treatment decisions.
NKI recognised that scaling its digital operations to further deliver on its commitment to excellent patient care would require moving away from its legacy software system. It selected the enterprise-grade Concentriq Dx to serve as the modern platform at the centre of its growing oncology practice. The new platform will also allow the cancer center, which houses an internationally acclaimed research institute, to generate additional pathology data that can lead to clinical breakthroughs.
CE-marked under IVDR, Concentriq Dx is a singular, secure digital pathology platform that drives primary diagnostic and other routine workflows across the connected laboratory. NKI will draw on the platform’s interoperability to unify images from disparate scanners, bringing more pathology data into its practice. With live and asynchronous collaboration and remote image viewing, Concentriq Dx helps pathologists to broaden access to specialists to provide higher quality diagnoses. The platform also offers interoperability with third-party image analysis applications, allowing NKI to identify clinically impactful patterns, and is designed for realising the promise of pathology’s computational future.
“Concentriq Dx will empower us to chart our path towards full digitisation,” said José van den Berg, Head of the Department of Pathology at NKI. “The modern, enterprise-grade platform will enable us to increasingly combine expertise and insight to drive precision diagnosis. Our multidisciplinary teams work to provide personalised treatment for all patients, and our pathology data plays an integral role in achieving this aim."
In addition to informing diagnoses, pathology data factors heavily into biomedical research that leads to new therapies and other breakthroughs that advance precision medicine and improve patient care. NKI’s internationally acclaimed research institute works closely with its dedicated cancer centre to create maximum impact for patients through foundational and translational clinical studies. By scaling its digital pathology practice, NKI is paving the way to unlock even more value from its growing volume of data by increasingly incorporating it into research initiatives.